basal ganglia disease: A disease involving the basal ganglia.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
600 |
4. Check minimum number of eventsNone |
600 |
5. Include endpointsNone |
600 |
6. Filter based on genotype QC (FinnGen only) |
583 |
Control definitions (FinnGen only)
- Control exclude
- G6_XTRAPYR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G20-G26
- Name in latin
- Alii morbi degenerativi gangliorum basalium
Similar endpoints
↥List of similar endpoints to
Other degenerative diseases of the basal ganglia
based on the number of shared cases.
Similar with more cases:
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4228 | 1862 | 2313 |
| Only index persons | 3359 | 1496 | 1863 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.05 | 0.06 |
| Only index persons | 0.06 | 0.05 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 72.48 | 72.52 | 72.47 |
| Only index persons | 72.80 | 72.69 | 72.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 583 | 228 | 355 |
| Unadjusted period prevalence (%) | 0.13 | 0.08 | 0.16 |
| Median age at first event (years) | 73.08 | 71.41 | 74.15 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 600
- Matched controls
- 6000
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
+∞
319.2
277
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
+∞
307.7
313
*
G20
ICD-10 Finland
Parkinson disease
+∞
307.7
317
*
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
760.5
307.7
452
24
N87
ICPC
Parkinsonism
1524.8
222.6
203
*
G23.1
ICD-10 Finland
Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
+∞
216.1
194
*
G23.8
ICD-10 Finland
Other specified degenerative diseases of basal ganglia
+∞
130.0
120
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
313.7
105.5
104
*
R25.1
ICD-10 Finland
Tremor, unspecified
18.0
94.0
79
50
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.9
82.3
150
276
L28
ICPC
Limited function/disability (L)
4.8
76.0
261
833
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
+∞
71.3
67
*
N04BC05
ATC
pramipexole; oral
7.0
69.1
120
208
R4130
NOMESCO Finland
Speech therapy
13.3
68.9
68
57
N99
ICPC
Neurological disease other
18.8
67.8
55
32
N04BD01
ATC
selegiline; oral
194.5
67.6
69
*
N04BC04
ATC
ropinirole; oral
181.8
63.3
65
*
N06DA03
ATC
rivastigmine; oral, transdermal
7.3
60.5
98
157
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
10.3
60.4
71
77
D21
ICPC
Swallowing problem
14.6
60.4
56
42
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
+∞
58.3
55
*
A28
ICPC
Limited function/disability NOS
3.8
54.0
239
882
AA1AD
NOMESCO Finland
CT of head and brain
3.7
53.8
311
1365
N05AH04
ATC
quetiapine; oral
4.4
52.4
168
492
G23.2
ICD-10 Finland
Multiple system atrophy, parkinsonian type [MSA-P]
+∞
51.8
49
*
R53
ICD-10 Finland
Malaise and fatigue
3.7
51.1
251
986
SPAT1229
SPAT
Assessment of need for aid
4.9
50.6
131
324
N03AE01
ATC
clonazepam; systemic
6.7
47.5
81
136
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
14.3
47.3
44
33
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.5
46.2
236
940
SPAT1216
SPAT
Assessment of functional ability
3.6
46.1
211
784
N04BD02
ATC
rasagiline; oral
+∞
45.4
43
*
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
10.0
43.3
51
55
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.9
43.0
106
250
N19
ICPC
Speech disorder
14.3
42.0
39
29
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.0
40.8
141
430
G04BD12
ATC
mirabegron; oral
3.6
39.2
164
568
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
+∞
39.0
37
*
N28
ICPC
Limited function/disability (N)
10.4
37.8
43
44
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
390.4
37.4
37
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.9
36.6
293
1472
R5110, ,
SPAT
4.6
35.8
96
241
R13
ICD-10 Finland
Dysphagia
4.3
35.5
102
270
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
33.4
180
721
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.9
33.0
113
339
XA800
NOMESCO Finland
Neuropsychological investigation
6.9
33.0
53
83
SPAT1231
SPAT
Assessment of adjustments needed in living environment
7.6
32.7
48
68
G90.3
ICD-10 Finland
Multi-system degeneration
+∞
30.5
29
*
A06AD11
ATC
lactulose; oral
3.1
29.9
163
652
N06AB10
ATC
escitalopram; oral
3.3
29.7
137
497
G25.0
ICD-10 Finland
Essential tremor
11.6
29.6
31
28
193
Kela drug reimbursment
Rasagiline
+∞
29.4
28
*
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
+∞
29.4
28
*
I95.1
ICD-10 Finland
Orthostatic hypotension
5.0
29.2
67
147
R47.1
ICD-10 Finland
Dysarthria and anarthria
10.0
29.1
34
36
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
6.3
28.4
50
86
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
8.8
28.1
36
43
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.0
28.1
87
242
N29
ICPC
Neurological sympt/complt other
8.5
28.0
37
46
S01.0
ICD-10 Finland
Open wound of scalp
3.7
27.9
100
308
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.9
27.7
89
254
A04
ICPC
Weakness/tiredness general
3.1
27.5
144
560
TAB00
NOMESCO Finland
Lumbar puncture
5.1
26.8
59
125
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.5
26.4
257
1370
G23.3
ICD-10 Finland
Multiple system atrophy, cerebellar type [MSA-C]
+∞
26.2
25
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
10.1
26.1
30
31
N06AX11
ATC
mirtazapine; oral
2.5
25.5
249
1324
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.2
25.3
55
115
N04BC09
ATC
rotigotine; transdermal
260.4
24.9
25
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.7
24.1
160
703
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.8
24.0
144
600
N04BX02
ATC
entacapone; oral
+∞
23.1
22
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.1
23.0
68
182
N04AA02
ATC
biperiden; systemic
9.7
22.8
27
29
SPAT1234
SPAT
Support of social functional capacity
4.1
22.6
66
175
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.7
22.0
75
222
H02AA02
ATC
fludrocortisone; oral
21.1
21.9
32
16
R42
ICD-10 Finland
Dizziness and giddiness
2.4
21.6
197
1001
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
4.0
21.3
65
178
U04
ICPC
Incontinence urine
3.7
19.8
67
197
SPAT1294
SPAT
Other function in accordance with health social work nomenclature
5.6
19.0
37
70
M03BX01
ATC
baclofen; systemic
7.0
18.8
29
43
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.4
18.0
68
215
G31.8
ICD-10 Finland
Other specified degenerative diseases of nervous system
18.8
17.9
27
15
XF606
NOMESCO Finland
Ortostatic test
16.3
17.6
28
18
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.2
17.1
223
1294
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.9
17.0
52
142
SPAT1245
SPAT
Provision of support and information to patient’s family members
3.6
17.0
60
181
SPAT1254
SPAT
Administration of medicine
2.5
17.0
133
623
P20
ICPC
Memory disturbance
2.3
16.6
149
741
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.3
16.6
44
108
N03AG01
ATC
valproic acid; systemic, rectal
3.8
16.2
52
147
N30.0
ICD-10 Finland
Acute cystitis
2.5
15.7
111
494
N05BA04
ATC
oxazepam; oral
2.2
15.6
181
999
R1250
NOMESCO Finland
Evaluation of functional capability
5.9
15.5
28
49
N05AH03
ATC
olanzapine; systemic
4.0
15.5
46
123
W19
ICD-10 Finland
Unspecified fall
2.7
14.4
87
358
R32
ICD-10 Finland
Unspecified urinary incontinence
4.7
13.9
33
74
S01.1
ICD-10 Finland
Open wound of eyelid and periocular area
4.3
13.7
36
88
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.6
13.2
83
348
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
29.1
13.0
17
6
S01.8
ICD-10 Finland
Open wound of other parts of head
6.3
13.0
22
36
N02AA05
ATC
oxycodone; systemic
2.1
12.7
160
901
N04BB01
ATC
amantadine; oral
10.4
12.6
24
24
R4110
NOMESCO Finland
Physiotherapy
2.0
12.6
199
1214
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.3
12.5
49
158
R4120, ,
SPAT
13.6
12.5
21
16
R4130, ,
SPAT
132.7
12.5
13
*
C07AA05
ATC
propranolol; systemic
2.2
12.4
114
568
N06AB04
ATC
citalopram; systemic
2.1
12.0
137
742
G21.1
ICD-10 Finland
Other drug-induced secondary parkinsonism
122.3
11.5
12
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.7
11.4
63
247
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.8
11.3
61
236
N06AX16
ATC
venlafaxine; oral
2.4
11.3
83
374
R1250, ,
SPAT
5.5
10.9
21
39
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.2
10.8
104
525
G91.2
ICD-10 Finland
Normal-pressure hydrocephalus
4.9
10.8
24
51
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.5
10.6
74
325
K59.09
ICD-10 Finland
Constipation, unspecified
2.6
10.6
63
256
N04BX04
ATC
opicapone; oral
+∞
10.4
10
*
AA5DR
NOMESCO Finland
Brain metabolism PET with CT
+∞
10.4
10
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.1
10.4
44
149
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
10.3
77
349
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
8.7
10.1
21
25
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
4.9
10.1
22
46
G25.2
ICD-10 Finland
Other specified forms of tremor
40.8
10.0
12
*
S06.0
ICD-10 Finland
Concussion
2.3
10.0
79
368
N05BA06
ATC
lorazepam; systemic, sublingual
2.9
9.8
48
177
N05AX08
ATC
risperidone; systemic
2.5
9.6
65
282
Z3226
NOMESCO Finland
Physiotherapist
1.9
9.4
129
740
SPAT1301
SPAT
No procedures
1.7
9.3
216
1460
R1260
NOMESCO Finland
Evaluation of communicative skills
4.3
9.3
24
58
G81.9
ICD-10 Finland
Hemiplegia, unspecified
8.5
9.1
19
23
R49.08
ICD-10 Finland
Other specified dysphonia
4.2
8.8
23
56
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
14.3
8.7
14
10
TJD20
NOMESCO Finland
Change of gastrostomy tube
14.3
8.7
14
10
K90
ICPC
Stroke/cerebrovascular accident
3.2
8.7
35
115
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
4.2
8.6
23
57
NA1AD
NOMESCO Finland
Cervical spine CT examination
2.9
8.6
41
149
SPAT1139
SPAT
Nutrition survey
3.2
8.5
33
106
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
3.9
8.4
25
67
R41.3
ICD-10 Finland
Other amnesia
3.2
8.4
33
107
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.0
8.4
108
606
G23.0
ICD-10 Finland
Hallervorden-Spatz disease
+∞
8.3
8
*
G24.9
ICD-10 Finland
Dystonia, unspecified
+∞
8.3
8
*
G21.8
ICD-10 Finland
Other secondary parkinsonism
+∞
8.3
8
*
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.4
8.3
60
268
H50.52
ICD-10 Finland
Exophoria
7.7
8.2
18
24
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.9
8.2
107
603
N06AX21
ATC
duloxetine; oral
2.2
8.1
67
318
R33
ICD-10 Finland
Retention of urine
2.1
8.1
82
422
M48.0
ICD-10 Finland
Spinal stenosis
1.9
7.9
104
587
F03
ICD-10 Finland
Unspecified dementia
2.7
7.9
41
156
N18
ICPC
Paralysis/weakness
3.9
7.9
23
61
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
7.1
7.8
18
26
T08
ICPC
Weight loss
4.4
7.7
19
44
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
2.7
7.7
40
152
L89
ICD-10 Finland
Decubitus ulcer and pressure area
4.1
7.7
21
53
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.7
7.6
24
67
Z2445
NOMESCO Finland
Psychologist
3.8
7.5
23
63
R4110, ,
SPAT
2.2
7.5
65
314
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.0
7.5
84
448
K91
ICPC
Cerebrovascular disease
4.5
7.5
18
41
IGY02
NOMESCO Finland
Psychiatric monitoring contact
6.1
7.4
19
32
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.0
7.4
92
509
TKC20
NOMESCO Finland
Catheterisation of bladder
2.2
7.3
63
303
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
+∞
7.3
7
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.6
7.2
267
2003
R63.4
ICD-10 Finland
Abnormal weight loss
2.9
7.2
33
117
S00.0
ICD-10 Finland
Superficial injury of scalp
3.6
7.2
23
65
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
3.6
7.1
23
66
SPAT1053
SPAT
Memory test
1.7
7.0
134
847
N06AX26
ATC
vortioxetine; oral
2.8
7.0
34
125
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
6.4
7.0
17
27
N05AH02
ATC
clozapine; systemic
9.5
6.8
13
14
UKC02
NOMESCO Finland
Cystoscopy
1.7
6.8
135
863
K11.72
ICD-10 Finland
Xerostomia
40.5
6.8
8
*
SPAT1240
SPAT
Therapeutic discussion
2.4
6.7
45
195
G40.9
ICD-10 Finland
Epilepsy, unspecified
3.0
6.7
29
100
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.6
6.6
188
1319
G31.0
ICD-10 Finland
Circumscribed brain atrophy
8.8
6.6
13
15
X59
ICD-10 Finland
Exposure to unspecified factor
1.8
6.6
114
700
NE1AA
NOMESCO Finland
Pelvis X-ray examination
2.1
6.6
61
303
IGY99
NOMESCO Finland
Other psychiatric treatment contact
10.2
6.6
12
12
SPAT1125
SPAT
Stoma care and guidance
4.0
6.5
18
46
G04CB01
ATC
finasteride; oral
1.8
6.5
112
687
N17
ICPC
Vertigo/dizziness
1.9
6.4
87
494
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
70.6
6.4
7
*
N03AX14
ATC
levetiracetam; systemic
3.2
6.4
25
81
R35
ICD-10 Finland
Polyuria
2.2
6.4
56
272
S01.41
ICD-10 Finland
Open wound in the temple-jaw region
6.1
6.3
16
27
AA400
NOMESCO Finland
Electroconvulsive therapy
11.2
6.3
11
10
SPAT1042
SPAT
Guidance concerning balance maintenance
9.4
6.3
12
13
R5130, ,
SPAT
18.2
6.3
9
5
N04BC02
ATC
pergolide; oral
+∞
6.3
6
*
R4120
NOMESCO Finland
Occupational therapy
2.3
6.2
45
201
D12
ICPC
Constipation
2.6
6.2
34
133
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.0
6.2
68
359
S22.3
ICD-10 Finland
Fracture of rib
2.2
6.2
55
268
K03.66
ICD-10 Finland
Tooth plaque
2.3
6.2
48
222
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
4.2
6.1
16
39
130
Kela drug reimbursment
Malignant tumour
0.2
6.1
11
434
R27.0
ICD-10 Finland
Ataxia, unspecified
8.7
6.1
12
14
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
6.8
6.1
14
21
SPAT1167
SPAT
Insertion of urinary catheter
2.6
6.1
33
129
SPAT1172
SPAT
Guidance concerning hydration
3.5
6.1
20
58
Z50.5
ICD-10 Finland
Speech therapy
6.1
6.0
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
313
1697
2.77
32.84
2.6
2.1
251.32
270.87
u/l
0.11
297
1590
39
46
9.00
30.82
1.1
1.0
217.60
324.14
ng/l
1.47
25
28
39
46
9.00
30.82
1.1
1.0
31.73
44.63
ng/l
1.20
22
27
58
109
5.78
30.07
1.3
1.2
2.36
87.80
e6/l
0.93
42
86
58
109
5.78
30.07
1.4
1.3
313.95
1315.72
e6/l
0.48
43
89
38
46
8.75
29.41
1.1
1.0
620.27
533.89
ng/l
0.53
22
27
156
706
2.63
21.95
2.0
1.8
—
—
—
0
0
153
710
2.55
20.28
2.1
1.8
—
—
—
0
0
195
1012
2.37
20.22
2.1
1.9
—
—
—
0
0
352
2376
2.16
18.64
2.4
2.1
89.56
93.04
pmol/l
0.88
202
1224
184
994
2.23
16.89
3.1
3.0
1.80
0.93
e6/l
0.53
104
596
208
1186
2.15
16.62
1.7
1.8
1150.60
1196.46
nmol/l
0.24
166
887
387
2794
2.08
16.13
6.0
7.4
1.22
1.21
mmol/l
1.72
337
2368
367
2601
2.06
16.06
5.2
6.5
1.22
1.21
mmol/l
1.35
339
2346
352
2468
2.03
15.74
4.5
5.1
34.63
34.72
g/l
0.11
331
2304
26
43
6.28
15.24
1.2
1.0
—
—
—
0
0
95
402
2.62
14.91
1.9
1.6
—
—
—
0
0
24
38
6.54
14.66
1.0
1.2
—
9.73
nmol/l
—
0
7
248
1575
1.98
14.31
3.6
3.4
0.48
0.54
e6/l
0.21
190
1223
28
54
5.39
14.03
1.1
1.0
—
—
—
0
0
232
1468
1.95
13.31
1.7
1.6
18.26
19.88
nmol/l
1.03
214
1217
282
1951
1.84
11.92
4.4
4.0
80.96
119.75
e6/l
0.49
203
1446
162
945
1.98
11.51
3.5
3.2
2.80
1.57
e6/l
0.77
85
552
337
2482
1.82
11.42
4.4
4.0
0.00
0.00
estimate
0.50
55
520
160
934
1.97
11.33
2.0
3.4
0.83
0.81
mmol/l
1.16
147
879
292
2064
1.81
11.31
3.6
3.4
—
—
—
0
0
253
1719
1.82
11.13
3.8
3.5
50.11
111.57
e6/l
0.87
189
1360
275
1924
1.79
10.91
2.3
3.6
2.35
2.34
mmol/l
0.07
236
1669
441
3593
1.86
10.04
3.6
3.7
15.34
15.05
pmol/l
1.50
400
3175
333
2510
1.73
9.82
4.4
4.0
0.00
0.01
estimate
0.50
52
468
327
2472
1.71
9.36
5.7
5.4
0.00
0.00
estimate
-0.00
50
486
400
3225
1.72
8.76
5.3
5.2
6.49
6.83
mmol/l
3.84
378
3052
71
337
2.26
8.55
1.5
1.5
—
—
—
0
0
303
2297
1.64
8.17
3.0
2.3
—
—
—
0
0
449
3770
1.76
8.16
3.9
4.3
13.18
14.18
mm/h
0.60
407
3429
166
1086
1.73
7.78
4.2
4.1
83.95
295.57
ng/l
2.57
141
942
274
2046
1.62
7.70
2.0
2.2
79.63
79.22
nmol/l
0.08
232
1771
173
1152
1.71
7.58
2.8
3.3
2.44
2.45
mmol/l
0.81
155
1015
50
218
2.41
7.30
2.0
2.3
629.14
642.08
ug/l
0.01
43
207
178
1213
1.66
7.08
2.6
2.7
5.52
4.40
e6/l
0.60
154
1106
503
4442
1.82
6.77
4.9
4.6
1.88
2.32
mu/l
0.89
461
3942
181
1251
1.64
6.76
1.6
1.8
444.24
20432649.90
pmol/l
1.04
150
1018
10
6
16.92
6.76
11.0
20.0
1141.40
1403.67
nmol/l
—
10
6
10
6
16.92
6.76
7.8
14.5
639.30
617.17
nmol/l
—
10
6
464
4021
1.68
6.51
6.1
8.2
76.76
81.43
u/l
1.73
437
3743
161
1096
1.64
6.33
4.8
4.4
1.02
1.02
kg/l
0.41
23
169
17
32
5.44
6.19
1.1
1.0
—
—
—
0
0
535
4862
1.93
5.94
22.7
17.4
31.94
27.09
mg/l
2.42
483
3963
136
911
1.64
5.64
1.3
1.2
2.02
1.36
u/ml
0.19
25
231
151
1067
1.55
4.95
1.3
1.7
1.37
1.41
mg/l
0.04
113
846
184
1363
1.50
4.83
3.6
4.2
82.49
85.68
%
0.94
179
1329
88
547
1.71
4.81
3.1
3.2
129.38
229.86
ng/l
3.97
80
498
196
1479
1.48
4.68
2.3
2.2
2.85
3.12
mg/l
0.92
162
1252
134
939
1.55
4.52
1.6
1.9
29.91
30.02
s
0.08
129
905
12
23
5.30
4.47
1.3
1.1
—
—
—
0
0
347
2932
1.44
4.47
8.0
9.4
4.32
4.23
e9/l
0.30
286
2570
87
552
1.67
4.41
2.1
3.2
65.64
65.61
g/l
0.01
79
497
37
183
2.09
4.08
1.2
1.2
—
—
—
0
0
272
2228
1.40
4.02
4.5
4.1
42.32
56.84
ng/l
0.42
225
1750
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
12
28
4.35
3.83
1.3
1.1
—
—
—
0
0
179
1383
1.42
3.63
5.2
4.3
0.00
0.01
estimate
0.50
51
450
10
21
4.82
3.57
1.5
1.2
—
—
—
0
0
105
738
1.51
3.45
6.1
7.8
11.88
11.87
kpa
0.01
100
711
99
1378
0.66
3.45
1.5
1.7
1.20
1.31
mmol/l
0.89
88
1115
249
2050
1.37
3.41
2.4
2.8
151.97
165.39
ug/l
0.44
225
1857
66
421
1.64
3.29
1.7
1.7
—
—
—
0
0
84
568
1.56
3.29
2.0
2.2
0.20
0.21
g/l
0.10
75
530
7
11
6.42
3.19
1.0
1.0
—
—
—
0
0
338
2939
1.34
3.16
3.2
3.3
47.24
57.25
u/l
1.06
306
2679
103
741
1.47
3.02
6.2
7.8
1.86
1.18
mmol/l
0.81
88
589
546
5165
1.63
3.02
27.1
21.0
139.63
139.62
mmol/l
0.03
538
5018
9
21
4.33
3.00
1.0
1.4
30.89
29.81
umol/l
—
9
21
229
1891
1.34
2.98
5.0
4.3
—
—
—
0
0
98
701
1.48
2.96
9.6
8.6
—
—
—
0
0
12
37
3.29
2.94
3.2
2.5
—
—
—
0
0
546
5174
1.61
2.88
27.2
21.2
3.95
4.01
mmol/l
7.29
537
5025
45
272
1.71
2.77
2.0
1.9
1.22
3.95
ug/l
0.87
33
240
80
562
1.49
2.65
2.0
2.7
9.12
6.92
ug/l
0.40
65
497
7
15
4.71
2.60
1.0
1.0
—
—
—
0
0
66
450
1.52
2.52
1.9
4.1
73.41
94.50
ng/l
1.26
54
394
323
2848
1.29
2.47
4.7
6.8
11.04
12.23
umol/l
1.80
300
2706
8
21
3.85
2.47
1.4
1.1
—
—
—
0
0
276
2394
1.28
2.37
4.3
5.7
58.28
58.52
%
0.11
256
2237
7
17
4.15
2.36
1.1
1.1
—
—
—
0
0
7
17
4.15
2.36
1.1
1.1
—
—
—
0
0
7
17
4.15
2.36
1.1
1.1
—
—
—
0
0
279
2428
1.28
2.32
4.5
5.9
25.51
25.92
%
0.21
259
2261
68
477
1.48
2.28
2.0
2.5
30.39
33.77
u/l
0.59
59
404
46
296
1.60
2.27
3.0
4.2
25.17
24.15
mmol/l
1.05
46
290
7
18
3.92
2.25
1.1
1.1
—
—
—
0
0
7
18
3.92
2.25
1.1
1.1
—
—
—
0
0
68
480
1.47
2.22
1.9
2.1
397.53
379.84
nmol/l
0.36
57
437
5
9
5.59
2.21
1.2
1.0
—
—
—
0
0
23
122
1.92
2.19
1.2
1.4
—
—
—
0
0
36
220
1.68
2.17
2.8
2.8
1.12
1.44
g/l
0.21
31
191
38
236
1.65
2.16
3.4
4.3
25.76
25.05
mmol/l
1.03
33
221
58
402
1.49
2.08
6.0
10.0
0.72
0.68
%
0.25
58
397
59
411
1.48
2.06
1.5
1.7
1.49
1.68
%
2.02
46
331
58
405
1.48
2.01
6.2
9.8
1.32
1.36
%
0.14
58
400
40
257
1.60
2.01
3.3
2.8
—
—
—
0
0
57
400
1.47
1.93
6.2
10.2
93.30
94.02
%
0.34
57
395
21
114
1.87
1.89
1.4
1.3
—
—
—
0
0
21
114
1.87
1.89
1.4
1.3
—
—
—
0
0
80
603
1.38
1.84
2.3
2.9
6.21
9.14
umol/l
2.08
68
541
20
108
1.88
1.83
1.3
1.1
—
—
—
0
0
10
219
0.45
1.80
1.3
1.8
—
—
—
0
0
278
2472
1.23
1.77
2.8
2.8
—
—
—
0
0
37
243
1.56
1.72
2.5
3.5
1.08
1.38
mmol/l
1.37
37
235
5
13
3.87
1.72
1.4
1.0
2313.00
1671.15
miu/ml
—
5
13
0
46
0.00
1.71
0.0
1.0
—
—
—
0
0
76
579
1.36
1.65
3.3
3.8
2.69
1.99
mmol/l
0.69
69
482
195
1683
1.24
1.62
2.7
2.5
54.21
109.10
u/l
0.60
173
1552
312
2827
1.22
1.60
19.0
18.9
1.29
1.36
inr
0.67
80
793
233
2051
1.22
1.60
4.4
4.8
20.50
21.52
%
0.54
110
1096
37
249
1.52
1.56
1.7
1.9
—
—
—
0
0
23
138
1.69
1.54
1.1
1.2
—
—
—
0
0
45
317
1.45
1.53
1.3
2.1
1.47
1.53
g/l
0.20
39
280
0
42
0.00
1.53
0.0
1.1
—
85.40
—
0
5
0
44
0.00
1.51
0.0
1.2
—
—
—
0
0
23
139
1.68
1.50
1.1
1.2
—
—
—
0
0
182
1575
1.22
1.46
2.9
3.3
28.84
32.90
u/l
1.43
167
1496
107
873
1.27
1.44
2.1
2.6
2.12
2.25
g/l
1.38
96
815
9
39
2.33
1.43
1.1
1.2
—
—
—
0
0
9
39
2.33
1.43
1.1
1.2
—
—
—
0
0
25
157
1.62
1.43
1.6
1.5
179.92
263.96
ug/g
1.50
13
93
34
230
1.51
1.42
1.7
1.7
—
—
—
0
0
546
5284
1.37
1.41
32.5
26.0
38.80
39.58
%
2.20
505
4898
546
5285
1.37
1.40
32.5
25.7
237.47
237.31
e9/l
0.02
531
5123
546
5286
1.37
1.39
32.5
25.7
4.32
4.42
e12/l
4.96
530
5096
546
5287
1.36
1.38
32.7
25.9
129.88
133.70
g/l
7.42
538
5176
5
17
2.96
1.36
1.0
1.1
—
—
—
0
0
5
18
2.79
1.28
1.2
1.1
—
—
—
0
0
13
70
1.88
1.24
2.3
2.6
—
—
—
0
0
57
733
0.75
1.23
4.1
4.9
34.35
32.15
%
0.92
40
478
279
2547
1.18
1.21
4.7
5.6
4.23
3.26
ug/l
0.21
245
2248
113
950
1.23
1.19
2.1
2.6
10.82
12.47
umol/l
2.15
101
887
33
232
1.45
1.18
1.3
1.2
131.11
184.83
u/ml
0.58
28
208
49
370
1.35
1.17
3.1
3.8
2.85
2.13
mmol/l
0.62
32
282
0
34
0.00
1.16
0.0
1.2
—
—
—
0
0
0
34
0.00
1.16
0.0
1.2
—
—
—
0
0
0
35
0.00
1.15
0.0
1.2
—
—
—
0
0
0
35
0.00
1.15
0.0
1.2
—
—
—
0
0
0
35
0.00
1.15
0.0
1.2
—
—
—
0
0
0
36
0.00
1.14
0.0
1.2
—
—
—
0
0
100
834
1.24
1.14
2.3
2.7
19.76
22.32
%
1.29
77
716
51
390
1.34
1.13
1.7
2.2
13.60
12.14
nmol/l
0.57
44
335
55
692
0.77
1.03
2.6
4.4
2.71
30.06
ug/l
1.66
39
595
464
4814
0.84
0.99
4.4
4.9
4.30
4.44
mmol/l
2.05
420
4371
150
1321
1.18
0.98
2.4
2.6
—
—
—
0
0
5
23
2.18
0.98
1.2
1.2
—
—
—
0
0
26
182
1.45
0.97
1.1
1.3
—
—
—
0
0
7
36
1.96
0.97
1.4
1.2
—
—
—
0
0
12
69
1.75
0.97
2.7
4.1
—
—
—
0
0
164
1463
1.17
0.92
2.9
3.3
0.62
0.79
ug/l
1.72
125
1046
6
29
2.08
0.89
1.5
1.3
—
—
—
0
0
460
4761
0.86
0.86
4.2
4.9
1.42
1.44
mmol/l
0.43
413
4275
74
619
1.22
0.85
5.4
3.7
—
—
—
0
0
12
73
1.66
0.82
1.2
1.5
—
—
—
0
0
0
25
0.00
0.79
0.0
1.0
—
—
—
0
0
0
25
0.00
0.79
0.0
2.2
—
—
—
0
0
0
25
0.00
0.79
0.0
2.2
—
—
—
0
0
14
90
1.57
0.78
2.2
1.7
—
—
—
0
0
0
26
0.00
0.78
0.0
2.1
—
—
—
0
0
0
26
0.00
0.78
0.0
1.1
—
292.69
—
0
16
0
27
0.00
0.77
0.0
1.3
—
—
—
0
0
6
34
1.77
0.76
1.5
1.6
—
—
—
0
0
10
59
1.71
0.76
1.0
1.3
—
—
—
0
0
49
397
1.26
0.76
3.2
3.8
5.20
5.19
kpa
0.02
44
379
12
75
1.61
0.75
1.2
1.5
—
—
—
0
0
12
75
1.61
0.75
1.2
1.5
—
—
—
0
0
12
75
1.61
0.75
1.2
1.5
—
—
—
0
0
12
75
1.61
0.75
1.2
1.5
—
—
—
0
0
14
92
1.53
0.73
1.2
1.3
—
—
—
0
0
5
25
2.01
0.73
2.8
2.5
71.20
83.56
nmol/l
—
5
25
7
39
1.80
0.72
1.1
1.4
—
—
—
0
0
6
110
0.54
0.72
1.0
1.3
64.23
41.30
u/l
—
6
95
17
117
1.47
0.72
1.5
1.6
—
—
—
0
0
12
76
1.59
0.72
1.2
1.5
—
—
—
0
0
9
142
0.63
0.70
1.8
1.3
—
—
—
0
0
12
181
0.66
0.70
1.3
1.6
—
132.50
—
0
8
9
58
1.56
0.70
1.4
1.4
—
—
—
0
0
15
102
1.48
0.68
1.6
1.3
—
—
—
0
0
5
92
0.54
0.67
3.2
2.8
—
821.50
—
0
8
527
5154
1.18
0.67
10.5
11.7
22.11
25.15
u/l
2.97
507
4918
5
28
1.79
0.66
1.2
1.7
—
—
—
0
0
5
29
1.73
0.64
1.6
1.3
—
—
—
0
0
448
4608
0.89
0.59
3.9
4.4
1.19
1.27
mmol/l
1.92
401
4110
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
5
88
0.56
0.56
1.0
1.1
—
—
—
0
0
13
183
0.70
0.56
1.6
3.1
176.15
70.66
u/ml
0.32
13
176
31
381
0.80
0.53
1.3
1.4
—
—
—
0
0
210
1968
1.10
0.53
2.7
3.1
894.44
1600.67
ng/l
4.26
187
1725
9
62
1.46
0.53
1.0
1.3
0.58
0.57
nmol/l
—
9
56
5
85
0.58
0.45
1.2
1.1
—
—
—
0
0
12
86
1.40
0.44
3.9
2.9
4.56
4.47
e9/l
0.06
12
86
11
151
0.72
0.43
1.5
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
80
723
1.12
0.40
3.1
4.3
223.18
248.88
u/l
1.99
74
683
7
103
0.68
0.40
1.7
1.7
—
—
—
0
0
7
103
0.68
0.40
1.7
1.7
—
—
—
0
0
15
116
1.30
0.37
1.3
2.3
67.53
59.71
%
0.64
15
116
5
37
1.35
0.37
8.6
2.9
171.60
64.41
u/ml
—
5
37
8
116
0.69
0.37
1.0
1.3
—
—
—
0
0
179
1886
0.93
0.35
3.1
3.9
5.31
10.18
mg/mmol
1.56
125
1205
12
91
1.33
0.34
4.0
3.4
64.58
59.18
%
0.96
12
91
8
108
0.74
0.29
1.1
1.2
—
—
—
0
0
21
176
1.20
0.29
1.0
1.0
—
—
—
0
0
486
4927
0.93
0.27
5.1
5.5
2.45
2.57
mmol/l
2.42
439
4435
5
73
0.68
0.26
1.0
1.3
—
—
—
0
0
10
126
0.79
0.24
1.2
1.2
—
1.18
—
0
6
5
39
1.28
0.23
1.6
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
3.4
—
13.21
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
2.58
—
0
5
6
48
1.25
0.20
2.0
1.7
—
—
—
0
0
46
499
0.92
0.20
1.3
1.3
—
—
—
0
0
6
51
1.18
0.19
1.5
1.3
41.53
25.32
iu/l
—
6
43
11
132
0.83
0.18
2.0
1.5
—
—
—
0
0
7
58
1.21
0.18
1.3
1.3
—
—
—
0
0
10
82
1.22
0.17
1.4
1.6
—
—
—
0
0
20
225
0.89
0.16
4.0
3.9
—
2.20
—
0
16
141
1459
0.96
0.16
2.4
3.0
3647.76
8434.14
umol/l
0.72
116
1246
38
409
0.92
0.15
3.0
3.0
57.18
58.07
ml/min/173m2
0.03
11
174
13
150
0.86
0.15
1.8
1.7
—
—
—
0
0
13
150
0.86
0.15
1.5
1.5
0.15
0.10
iu/ml
—
5
30
12
139
0.86
0.14
1.2
1.5
—
—
—
0
0
51
480
1.07
0.14
3.6
3.8
1.23
1.22
mmol/l
0.53
41
421
12
103
1.17
0.14
1.8
1.6
—
—
—
0
0
25
228
1.10
0.13
1.0
1.2
79.62
126.83
iu/ml
—
9
84
15
169
0.88
0.13
2.7
2.4
37.27
97.82
ug/min
—
9
98
472
4683
1.04
0.12
6.1
6.7
39.31
40.91
mmol/mol
4.07
427
4280
13
147
0.88
0.11
1.3
1.9
—
—
—
0
0
71
740
0.95
0.11
1.3
1.2
20.52
38.52
iu/ml
1.35
18
229
468
4645
1.03
0.11
19.7
16.7
78.20
73.25
ml/min/173m2
6.68
400
3867
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
238
0.92
0.10
2.5
2.5
0.35
0.35
u/ml
0.04
12
133
6
55
1.09
0.09
1.3
1.1
—
—
—
0
0
17
185
0.92
0.08
1.9
1.6
—
—
—
0
0
5
60
0.83
0.08
1.0
2.0
—
—
—
0
0
5
65
0.77
0.08
1.0
1.0
—
—
—
0
0
7
66
1.06
0.08
1.9
1.7
—
—
—
0
0
6
71
0.84
0.07
1.8
1.5
—
—
—
0
0
6
71
0.84
0.07
1.8
1.5
—
—
—
0
0
176
1787
0.98
0.07
2.7
3.2
7.90
7.30
mmol/l
0.98
145
1447
9
84
1.07
0.07
1.7
1.6
—
—
—
0
0
13
142
0.91
0.06
1.8
1.7
—
—
—
0
0
69
708
0.97
0.06
1.3
1.2
7.68
12.80
u/ml
0.33
24
250
18
169
1.07
0.05
1.5
1.3
—
—
—
0
0
10
91
1.10
0.04
1.9
1.6
—
—
—
0
0
12
129
0.93
0.03
2.6
2.7
16.67
15.71
%
—
6
67
19
181
1.05
0.03
1.4
1.7
—
—
—
0
0
11
118
0.93
0.03
1.8
1.4
—
—
—
0
0
485
4838
1.01
0.02
5.0
5.2
6.02
6.11
mmol/l
0.98
430
4319
23
223
1.03
0.01
2.0
2.9
—
—
—
0
0
10
106
0.94
0.01
1.6
1.8
—
—
—
0
0
10
97
1.03
0.00
1.2
1.7
41.80
45.01
nmol/l
—
10
89
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
58
0.86
0.00
1.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
96.75
—
0
8
5
58
0.86
0.00
1.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.9
—
—
—
0
0
5
58
0.86
0.00
1.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
8.02
—
0
5
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
81.29
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
-0.00
1.6
1.1
—
—
—
0
0
8
81
0.99
-0.00
2.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
63
0.95
-0.00
1.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_BASDEGENOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_BASDEGENOTH | 5.541 [4.56, 6.72] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.285 |
During the follow-up period (1.1.1998 — 31.12.2019), 710 out of 1242 females with G6_BASDEGENOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_BASDEGENOTH | 4.925 [3.86, 6.29] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 960 out of 1580 males with G6_BASDEGENOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_BASDEGENOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.511% | 0.88% |
| 5 | 3.368% | 5.096% |
| 10 | 8.029% | 12.307% |
| 15 | 14.69% | 22.676% |
| 20 | 24.56% | 35.996% |
Relationships between endpoints
↥Index endpoint: G6_BASDEGENOTH – Other degenerative diseases of the basal ganglia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data